Exploring the Impact of ACE Inhibition in Immunity and Disease
| dc.contributor.author | Oosthuizen, Delia | |
| dc.contributor.author | Sturrock, Edward | |
| dc.date.accessioned | 2022-10-13T13:26:21Z | |
| dc.date.available | 2022-10-13T13:26:21Z | |
| dc.date.issued | 2022-08-04 | |
| dc.description.abstract | Angiotensin-converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase and is crucial in the renin-angiotensin aldosterone system (RAAS) but also implicated in immune regulation. Intrinsic ACE has been detected in several immune cell populations, including macrophages and neutrophils, where its overexpression results in enhanced bactericidal and antitumour responses, independent of angiotensin II. With roles in antigen presentation and inflammation, the impact of ACE inhibitors must be explored to understand how ACE inhibition may impact our ability to clear infections or malignancy, particularly in the wake of the coronavirus (SARS-CoV2) pandemic and as antibiotic resistance grows. Patients using ACE inhibitors may be more at risk of postsurgical complications as ACE inhibition in human neutrophils results in decreased ROS and phagocytosis whilst angiotensin receptor blockers (ARBs) have no effect. In contrast, ACE is also elevated in certain autoimmune diseases such as rheumatoid arthritis and lupus, and its inhibition benefits patient outcome where inflammatory immune cells are overactive. Although the ACE autoimmune landscape is changing, some studies have conflicting results and require further input. This review seeks to highlight the need for further research covering ACE inhibitor therapeutics and their potential role in improving autoimmune conditions, cancer, or how they may contribute to immunocompromise during infection and neurodegenerative diseases. Understanding ACE inhibition in immune cells is a developing field that will alter how ACE inhibitors are designed in future and aid in developing therapeutic interventions. | en_US |
| dc.identifier.apacitation | Oosthuizen, D., & Sturrock, E. (2022). Exploring the Impact of ACE Inhibition in Immunity and Disease. <i>Journal of the Renin-Angiotensin-Aldosterone System</i>, 2022 1-16. http://hdl.handle.net/11427/36834 | en_ZA |
| dc.identifier.chicagocitation | Oosthuizen, Delia, and Edward Sturrock "Exploring the Impact of ACE Inhibition in Immunity and Disease." <i>Journal of the Renin-Angiotensin-Aldosterone System</i> 2022, (2022): 1-16. http://hdl.handle.net/11427/36834 | en_ZA |
| dc.identifier.citation | Oosthuizen, D. & Sturrock, E. 2022. Exploring the Impact of ACE Inhibition in Immunity and Disease. <i>Journal of the Renin-Angiotensin-Aldosterone System.</i> 2022:1-16. http://hdl.handle.net/11427/36834 | en_ZA |
| dc.identifier.ris | TY - Journal Article AU - Oosthuizen, Delia AU - Sturrock, Edward AB - Angiotensin-converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase and is crucial in the renin-angiotensin aldosterone system (RAAS) but also implicated in immune regulation. Intrinsic ACE has been detected in several immune cell populations, including macrophages and neutrophils, where its overexpression results in enhanced bactericidal and antitumour responses, independent of angiotensin II. With roles in antigen presentation and inflammation, the impact of ACE inhibitors must be explored to understand how ACE inhibition may impact our ability to clear infections or malignancy, particularly in the wake of the coronavirus (SARS-CoV2) pandemic and as antibiotic resistance grows. Patients using ACE inhibitors may be more at risk of postsurgical complications as ACE inhibition in human neutrophils results in decreased ROS and phagocytosis whilst angiotensin receptor blockers (ARBs) have no effect. In contrast, ACE is also elevated in certain autoimmune diseases such as rheumatoid arthritis and lupus, and its inhibition benefits patient outcome where inflammatory immune cells are overactive. Although the ACE autoimmune landscape is changing, some studies have conflicting results and require further input. This review seeks to highlight the need for further research covering ACE inhibitor therapeutics and their potential role in improving autoimmune conditions, cancer, or how they may contribute to immunocompromise during infection and neurodegenerative diseases. Understanding ACE inhibition in immune cells is a developing field that will alter how ACE inhibitors are designed in future and aid in developing therapeutic interventions. DA - 2022-08-04 DB - OpenUCT DP - University of Cape Town J1 - Journal of the Renin-Angiotensin-Aldosterone System KW - angiotensin-converting enzyme KW - autoimmunity KW - ACE inhibitors KW - lisinopril, captopril KW - angiotensin receptor blockers KW - inflammation LK - https://open.uct.ac.za PY - 2022 T1 - Exploring the Impact of ACE Inhibition in Immunity and Disease TI - Exploring the Impact of ACE Inhibition in Immunity and Disease UR - http://hdl.handle.net/11427/36834 ER - | en_ZA |
| dc.identifier.uri | http://hdl.handle.net/11427/36834 | |
| dc.identifier.vancouvercitation | Oosthuizen D, Sturrock E. Exploring the Impact of ACE Inhibition in Immunity and Disease. Journal of the Renin-Angiotensin-Aldosterone System. 2022;2022:1-16. http://hdl.handle.net/11427/36834. | en_ZA |
| dc.language.iso | en | en_US |
| dc.publisher.department | Department of Clinical Laboratory Sciences | en_US |
| dc.publisher.faculty | Faculty of Health Sciences | en_US |
| dc.source | Journal of the Renin-Angiotensin-Aldosterone System | en_US |
| dc.source.journalvolume | 2022 | en_US |
| dc.source.pagination | 1-16 | en_US |
| dc.source.uri | https://www.hindawi.com/journals/jraas/ | |
| dc.subject | angiotensin-converting enzyme | en_US |
| dc.subject | autoimmunity | |
| dc.subject | ACE inhibitors | |
| dc.subject | lisinopril, captopril | |
| dc.subject | angiotensin receptor blockers | |
| dc.subject | inflammation | |
| dc.title | Exploring the Impact of ACE Inhibition in Immunity and Disease | en_US |
| dc.type | Journal Article | en_US |